PDCD1 and neoplasm: Blockade of checkpoint inhibitors, primarily CTLA-4 and PD-1/PD-1L, has in many ways revolutionized cancer therapy by unleashing effector T cell responses resulting in enhanced tumor cell killing in the local tissue environment (178).